Singulex, Inc. Announces EMD Group (EMD Millipore Headquarters) To Acquire Exclusive Rights To Singulex’s Ultra-Sensitive Single Molecule Counting (SMC) Technology
Original article posted on BioSpace.
– EMD Millipore to acquire exclusive worldwide rights to Singulex’s SMCTM technology – instruments, assays and services – for research applications –
– Combination of Singulex’s Erenna® immunoassay platform and EMD Millipore’s global reach will accelerate SMC technology as “gold standard” for ultra-sensitive immunoassays –
– Singulex to leverage its superior immunoassay technology to create additional opportunities in existing diagnostics businesses –
ALAMEDA, Calif., May 21, 2015 (GLOBE NEWSWIRE) — Singulex, Inc., the developer and leading provider of Single Molecule Counting technology for clinical diagnostics and scientific discovery, today announced that they have entered into a definitive agreement under which EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, will control and manage the Singulex Life Science Research business, one of Singulex’s three areas of business. Under the terms of the agreement, EMD Millipore will pay Singulex an upfront payment, royalties and additional payments based upon achievement of certain commercial milestones. EMD Millipore will have exclusive rights to further develop and commercialize Singulex’s proprietary SMC™ technology for research applications worldwide.